Gleneagle Gold Ltd Is Well-Advanced In Transition To Medical Cannabis

May 05, 2016 9:22 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Short Only

Contributor Since 2009

Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily. We are one of the fastest growing financial media portals in the world. The group also operates hugely successful “investor forums” where three or four companies present to an audience of high net sophisticated investors, fund managers, hedge funds, private client brokers and analysts. Ian Mclelland founded Proactiveinvestors in 2006 as a way to channel his own views on companies small and mid-cap public companies. What started as a hobby quickly turned into a full time job as the website's readership exploded. One2One forums were added later in 2006, and within two years the company had expanded its operations into Canada and Australia. In 2009 the company expanded into Germany and finally into the US in 2010. Proactiveinvestors is now one of the fastest growing global financial media organizations in the world receiving more than one million visitors per month, with investor forums held across the globe on a regular basis.

Gleneagle Gold Ltd (ASX:GLN) is well-advanced in its transition into the medical cannabis sector, as it progresses the reverse takeover of Zelda Therapeutics, a California-based biotechnology company.

Gleneagle has issued 1.6 billion shares to acquire Zelda.

Gleneagle now plans to issue a prospectus and change its name to Zelda Therapeutics Limited.

Zelda has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group, Caziwell Inc., which operates the Aunt Zelda's group.

Zelda will use this information to design a series of phase 2-ready human clinical trials.

Zelda sees a strong probability of success given the existing patient data and experiences it has access to.

Road to commercialisation

Zelda has a clear commercialisation strategy, which begins with pre-clinical and clinical studies in-house.

The end goal is to out-license or partner with leading pharmaceutical and biotechnology companies for phase 3 trials and marketing.

The out-licensing revenue model consists of up-front and milestone payments and also royalties from marketed products.

Growth strategy

Zelda's growth strategy will be focused on developing existing products.

This means completing phase 2 clinical trials in dermatology indications and insomnia. It also means completing Spanish pre‐clinical research in cancer.

Zelda will then out‐license products with successful phase 2 results.

The secondary growth strategy will be expanding trials into new diseases and territories, which may come through partnerships.

A broad range of medical indications have been shown to be alleviated by medical cannabis

Zelda will also be looking at opportunities to merge and/or acquire as well as in-license new extracts for clinical testing and validation.

Strategic partnerships

Zelda has secured a number of partnerships with leaders in cannabis medicine.

It has an exclusive patient data access agreement in place with Aunt Zelda's, a pioneering, data‐driven developer of cannabis‐based medicines.

A manufacturing agreement is in place with AusCann, an Australian company working with one of the largest medical cannabis groups in the world to supply clinical trial material.

Zelda has a partnership with New Frontier, the leading cannabis data company based in the U.S. for data sharing.

Zelda also has exclusive access to CDRMed for clinical trial use, which is software which creates optimal formulations of medicinal cannabis based on the Aunt Zelda's database.

Finally, a partnership is also in place with the prestigious Complutense University Madrid for pre‐clinical research in cancer.

News flow pipeline

Pending a successful reverse takeover, the company has the following news flow pipeline:

- Commencement of pre‐clinical research in human breast cancer via Complutense University Madrid;
- Commencement of clinical trials in wound care and sleep disorders;
- Pre‐clinical trial results in cancer;
- Clinical trial results from acne, insomnia and wound trials;
- Commencement of observational trials in cancer; and
- Signing of partner for clinical trials in sleep and dermatology applications.

Highly active investment into the sector

Five companies in the US biotechnology sector completed 17 capital raises for a total of $217.4 million in 2015.

GW Pharmaceuticals (GWPH) secondary offering of American Depository Shares raised $206.1 million, with the company having a current market cap of circa US$1.6 billion.

NEMUS Bioscience (NMUS) raised a total of $7.2 million, including $5.0 million in its largest raise.

Axim Biotechnologies (OTCQB:AXIM) acquired Can Chew License for CanChew® gum, a unique patented controlled-release cannabinoid-infused chewing gum in 2015.


The application of medical cannabis in modern medicine is still growing and represents a diverse global opportunity.

Partnerships with New Frontier, CDRMed and Aunt Zelda could provide for the acceleration to phase 2 efficacy clinical trials.

Zelda has an active news flow pipeline with multiple near term share price catalysts.

With the Zelda valuation <$10 million, this provides material upside potential for incoming investors given median market capitalisation of Phase 2 ready biotechs listed on ASX is circa $50 million.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.